Oncotelic Therapeutics Inc (OTC: OTLC) is a clinical-stage oncology company that develops cancer therapeutics and an AI-enabled pharmaceutical research platform. The company generates no product revenue; it is funded through debt and equity issuances while advancing a pipeline of drug candidates and a proprietary AI platform called PDAOAI. Oncotelic operates primarily through a joint venture with GMP Bio, to which it transferred the bulk of its pipeline costs as of April 2022. Its lead drug candidates include OT-101, an inhibitor of the TGF-beta system, and CA4P (Fosbretabulin), a vascular disrupting agent being studied in combination with checkpoint inhibitors. As of December 31, 2025, the company held approximately $0.1 million in cash, carried approximately $11.9 million in short-term debt including accrued interest, and reported an accumulated deficit of approximately $38 million since inception, partially offset by a FY2025 fair-value gain on its GMP Bio investment of approximately $365.4 million (per the 10-K filed April 15, 2026).

Revenue model

Pre-revenue clinical-stage model. No product sales disclosed in the filing. Operations are financed through debt issuances and equity raises. A significant non-cash gain of approximately $365.4 million was recorded in FY2025 from a fair-value revaluation of the company's ownership interest in the GMP Bio joint venture.

Products and services

OT-101: a TGF-beta inhibitor in clinical trials for multiple cancers, including pancreatic cancer, developed through the GMP Bio joint venture. CA4P (Fosbretabulin/Fosbretabul): a vascular disrupting agent with FDA Rare Pediatric Disease designation, studied in combination with checkpoint inhibitors such as Ipilimumab. PDAOAI: a proprietary AI-enabled knowledge platform built around a TGF-beta-centric biomedical corpus of over 100,000 curated abstracts, designed for regulatory documentation, biomarker discovery, and scientific traceability in pharmaceutical R&D. The company is also developing an integrated AI and robotics platform in partnership with TechForce to automate GMP-compliant manufacturing workflows.

Customers and end markets

End markets are oncology patients across cancer indications including pancreatic cancer, glioblastoma, breast cancer, and pediatric melanoma. No commercial customers disclosed. The company is pre-commercial.

Value-chain role

Drug developer and AI platform operator. Oncotelic occupies an early-stage research and clinical development role, relying on third-party manufacturers for drug production and on the GMP Bio joint venture for advancing pipeline candidates. PDAOAI positions the company as an internal infrastructure provider for regulatory-grade scientific documentation and translational research.

Geographic exposure

Clinical trials being evaluated in the United States and China through the GMP Bio joint venture, per the 10-K filed April 15, 2026. No commercial geographic revenue mix disclosed.

Source: SEC 10-K, filed 2026-04-15

Industry: Pharmaceutical Preparations Peers: Forum Markets, Inc Serina Therapeutics Inc GeoVax Labs Inc eFFECTOR Therapeutics, Inc. Forte Biosciences Inc Vincerx Pharma, Inc. Oncorus, Inc. Regulus Therapeutics Inc. Tonix Pharmaceuticals Holding Corp